Condition 1: Obesity. Condition 2: Non-insulin-dependent diabetes mellitus. Condition 3: hypertriglyceridaemia. Condition 4: hypertension. Condition 5: High-density lipoprotein deficiency. Obesity Non-insulin-dependent diabetes mellitus Pure hyperglyceridaemia Essential (primary) hypertension Lipoprotein deficiency
Conditions
Interventions
Intervention 1: Simple Curcumin (unformulated). Intervention 2: Control group: placebo for 6 weeks. Intervention 3: Curcumin-phospholipid complex.
Treatment - Drugs
Placebo
Curcumin-phospholipid complex
Simple Curcumin (unformulated)
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : Men and women aged 18-65 years ; Metabolic Syndrome patients (based on IDF guidelines) ; Consent to participate in research project ; Not taking any dietary supplement ; Not taking any drugs within the last 3-6 months (Not history of taking any lipid-lowering, diabetes and hypertension drugs or insulin within the last 3-6 months) . Exclusion criteria : Lack of informed consent of patient to participate in research project ; Having systemic disease or history of systemic disease (such as lupus and kidney disease) ; Not having Metabolic Syndrome ; Pregnancy or lactation ; Consumption of any drug supplement or lipid-lowering drug within the last 3-6 months ; Metabolic syndrome subjects who need to take any drug (based on American Heart Association guidelines) .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglycerides. Timepoint: Baseline, week 6. Method of measurement: Routine enzymatic methods using standard biochemistry kits on an autonalyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Apo B. Timepoint: Baseline, week 6. Method of measurement: ELISA.;Apo A. Timepoint: Baseline, week 6. Method of measurement: ELISA.;Adiponectin. Timepoint: Baseline, week 6. Method of measurement: ELISA.;CETP. Timepoint: Baseline, week 6. Method of measurement: ELISA.;HS-CRP. Timepoint: Baseline, week 6. Method of measurement: immunoturbidimetric assay.;Lp (a). Timepoint: Baseline, week 6. Method of measurement: ELISA.;CBC. Timepoint: Baseline, week 6. Method of measurement: Sysmex KX-21 Hematology Analyzer.;Total cholesterol. Timepoint: Baseline, week 6. Method of measurement: Routine enzymatic methods using standard biochemistry kits on an autonalyzer.;HDL-c. Timepoint: Baseline, week 6. Method of measurement: Routine enzymatic methods using standard biochemistry kits on an autonalyzer.;LDL-c. Timepoint: Baseline, week 6. Method of measurement: Routine enzymatic methods using standard biochemistry kits on an autonalyzer.;Prooxidant-antioxidant balance. Timepoint: Baseline, week 6. Method of measurement: Colorimetric assay.;PON. Timepoint: Baseline, week 6. Method of measurement: ELISA.;Anti- HSP27. Timepoint: Baseline, week 6. Method of measurement: ELISA.;Interleukin-1ß (IL-1ß). Timepoint: Baseline, week 6. Method of measurement: biochip array immunoassay.;Interleukin-1a (IL-1a). Timepoint: Baseline, week 6. Method of measurement: biochip array immunoassay.;Interleukin-6 (IL-6). Timepoint: Baseline, week 6. Method of measurement: biochip array immunoassay.;Tumor necrosis factor (TNF-a). Timepoint: Baseline, week 6. Method of measurement: biochip array immunoassay.;Intercellular Adhesion Molecule-1 (ICAM-1),. Timepoint: Baseline, week 6. Method of measurement: ELISA.;L-Selectin. Timepoint: Baseline, week 6. Method of measurement: ELISA.;Anxiety. Timepoint: Baseline, week 6. Method of measurement: Questionnaire.;Depression. Timepoint: Baseline, week 6. Method of measurement: Questionnaire.;Vascular Cell Adhesion Molecule-1 (VCAM-1). Timepoint: Baseline, week 6. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Amirhossein Sahebkar
Mashhad University of Medical Sciences
Outcome results
None listed